Fresenius Medical Care AG (FMS) Form 6-K — Aug 27, 2026
Fresenius Medical Care announced the publication of a large multinational real-world evidence study in the Journal of the American Society of Nephrology associating hemodiafiltration (HDF) with a 28% lower relative risk of all-cause mortality compared with conventional high-flux hemodialysis. The study examined 19,539 adult dialysis patients across eight European countries treated between 2014 and 2019, with a median follow-up of 16 months.
Key figures
- Study period
- 2014-2019
- Patients analyzed
- 19539
- Countries in study
- 8
- Median followup months
- 16
- Dialysis clinics worldwide
- 3513
- Dialysis patients worldwide
- around 4.5 million
- Patients treated in clinics
- approx. 290,000
- Mortality risk reduction hdf
- 28% lower relative risk of all-cause mortality vs high-flux hemodialysis
- Mortality risk reduction hvhdf
- 33% lower relative risk of death with convection volumes above 23 liters per session
- Countries with hdf evidence base
- more than 90
- Convection volume threshold liters
- 23
- People with kidney disease worldwide
- more than 850 million (nearly 10% of world population)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.